<DOC>
	<DOCNO>NCT01527149</DOCNO>
	<brief_summary>This phase II trial study well ofatumumab combination cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , dexamethasone alternate ofatumumab combination cytarabine methotrexate work treat patient newly diagnose mantle cell lymphoma ( MCL ) . Monoclonal antibody , ofatumumab , may interfere ability cancer cell grow spread . Drugs use chemotherapy , cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , dexamethasone , cytarabine , methotrexate , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving ofatumumab together alternate regimen combination chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Ofatumumab Combination With Cyclophosphamide , Doxorubicin Hydrochloride , Vincristine Sulfate , Dexamethasone Alternating With Ofatumumab Combination With Cytarabine Methotrexate Treating Patients With Newly Diagnosed Mantle Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine overall response rate ( ORR ) , particular , complete remission rate ( CRR ) previously untreated MCL treat ofatumumab combination aggressive chemo-immunotherapy . SECONDARY OBJECTIVES : I . To determine high sensitivity flow cytometry ( HSFCM ) complete remission rate ( HSFCM-CRR ) previously untreated MCL treat ofatumumab combination aggressive chemo-immunotherapy +/- high dose chemotherapy autologous stem cell transplant ( HDC-ASCT ) . II . To determine time-to-progression ( TTP ) , progression-free survival ( PFS ) overall survival ( OS ) patient previously untreated MCL treat ofatumumab aggressive chemoimmunotherapy +/- HDC-ASCT . III . To determine toxicity profile ofatumumab combination high dose cytarabine chemoimmunotherapy +/- HDC-ASCT . IV . To correlate minimal residual disease ( MRD ) different time interval TTP , PFS , OS . V. To correlate surface cluster differentiation ( CD ) 20 level , Ki67 , additional cytogenetic abnormality pretreatment tumor biopsy respect ORR , CRR , TTP , PFS , OS . VI . To determine relationship proliferation signature clinical outcome use quantitative real-time reverse-transcriptase polymerase chain reaction ( RT-PCR ) . VII . To determine change surface CD20 level , Ki67 , gain additional cytogenetic abnormality relapsed/refractory tumor specimen . VIII . To correlate serum component ( C ) 3 , C4 , hemolytic complement ( CH ) 50 level measure baseline end first ofatumumab infusion ORR , CRR , median response rate ( MRR ) , TTP , PFS OS . IX . Evaluate ability induction consolidation therapy get 70 % patient autologous stem cell transplantation . X . Evaluate tolerability CD34+ cell yield follow therapy patient hyper-fractionated cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , dexamethasone ( HyperCVAD ) /high-dose cytarabine methotrexate ( HD-MA ) . XI . To compare difference response rate patient MCL treat ofatumumab + HyperCVAD/HD-MA accord Cheson Modified Cheson Criteria . OUTLINE : COURSES 1 , 3 , 5 ( O-HyperCVAD ) : Patients receive ofatumumab intravenously ( IV ) day 1 , cyclophosphamide IV 2 hour every 12 hour 6 dos day 3-5 , doxorubicin hydrochloride IV continuously 72 hour day 6-8 , vincristine sulfate IV day 6 13 , dexamethasone IV orally ( PO ) day 3-6 13-16 . COURSES 2 , 4 , 6 ( O-HD-MA ) : Patients receive ofatumumab IV day 1 , methotrexate IV continuously 24 hour day 3 , cytarabine IV 2 hour every 12 hour day 4-5 . Treatment repeat every 21 day 6* course absence disease progression unacceptable toxicity . Eligible patient undergo standard high dose chemotherapy autologous stem cell transplant ( HDC-ASCT ) . Patients achieve high sensitivity flow cytometry complete remission ( HSFCM-CR ) 2 course may proceed HDC-ASCT complete 4 course treatment . After completion study treatment , patient follow every 4 month 2 year , every 6 month 3 year , clinically instruct .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically document mantle cell lymphoma coexpression CD20 CD5 lack CD23 expression immunophenotyping least one follow confirmatory test : 1 ) positive immunostaining cyclin D1 ; 2 ) presence ( 11 ; 14 ) cytogenetic analysis ; OR 3 ) molecular evidence Bcell leukemia/lymphoma 1 ( bcl1 ) /immunoglobulin heavy locus ( IgH ) rearrangement Cases CD5negative and/or CD23positive eligible provide histopathology consistent mantle cell lymphoma AND positive cyclin D1 , ( 11 ; 14 ) , bcl1/IgH rearrangement A tissue block unstained slide ( 10 20 slide ) submit Roswell Park Cancer Institute ( RPCI ) Pathology Department central pathology review A diagnosis base peripheral blood bone marrow aspirate allow ; diagnosis base blood , addition immunophenotype molecular confirmation , peripheral blood smear must available central pathology review ; diagnosis base bone marrow , bone marrow core biopsy aspirate clot tissue block submit RPCI Pathology Department : tissue block available please submit diagnostic smear review Extent disease : stage I IV ; patient nodular histology mantle cell lymphoma must Ann Arbor stage III IV disease eligible Patients mantle zone type histology eligible Patients mantle cell histology eligible regardless stage Measurable assessable disease require ; measurable tumor size ( least one node measure 2.25 cm^2 bidimensional measurement ) No active central nervous system ( CNS ) disease define symptomatic meningeal lymphoma know CNS parenchymal lymphoma ; lumbar puncture demonstrate mantle cell lymphoma time registration study exclusion study enrollment Patients must previously untreated No prior radiation therapy mantle cell lymphoma &gt; = 2 week since major surgery No known hypersensitivity murine product No medical condition require chronic use high dose systemic corticosteroid ( i.e. , dose prednisone high 10 mg/day equivalent ) No human immunodeficiency virus ( HIV ) infection ; patient history intravenous drug abuse behavior associate increase risk HIV infection test exposure HIV virus ; patient test positive know infected eligible ; HIV test require entry protocol , require patient perceive risk Nonpregnant nonnursing ; woman men reproductive potential agree use effective mean birth control Patients test positive hepatitis C antibody ( Ab ) eligible provide follow criterion meet : 1 ) total bilirubin = &lt; 2 x upper limit normal ; 2 ) AND aspartate aminotransferase ( AST ) = &lt; 3 x upper limit normal ; AND 3 ) liver biopsy ( pathology ) demonstrate = &lt; grade 2 fibrosis cirrhosis Specific guideline follow regard inclusion MCL base hepatitis B serological testing follow : Hepatitis B surface antigen ( HBsAg ) negative , hepatitis B core antibody ( HBcAb ) negative , hepatitis B surface antibody ( HBsAb ) positive MCL patient eligible Patients test positive HBsAg ineligible ( regardless hepatitis B serology ) For MCL patient HBsAg negative , HBcAb positive ( regardless HBsAb status ) , hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) test do protocol eligibility determine follow : If HBV DNA positive subject exclude If HBV DNA negative , patient may include must undergo least every 2 month HBV DNA polymerase chain reaction ( PCR ) test start treatment throughout duration study Monitoring study require least every 2 month followup minimum every 23 month 6 month last dose Prophylactic antiviral therapy lamivudine ( 3TC ) investigator 's preferred antiviral regimen throughout protocol therapy 612 month thereafter may initiate discretion investigator If patient ' HBV DNA become positive study , investigator manage clinical situation per standard care participate institution ; investigator weigh risk benefit continue ofatumumab discontinue ofatumumab appropriate treatment decision make individual patient Patients must history cardiac disease , define New York Heart Association class II great clinical evidence congestive heart failure ( CHF ) No know hypersensitivity ofatumumab , humanize antibody chemotherapy agent throughout protocol Left ventricular ejection fraction ( LVEF ) multi gate acquisition scan ( MUGA ) echocardiogram ( ECHO ) &gt; = 45 % Neutrophils &gt; 1000/uL Platelets &gt; = 75,000/uL ( unless significant bone marrow involvement MCL ) Creatinine = &lt; 2.0 mg/dL Total bilirubin = &lt; 2.0 mg/dL ( unless MCL relate attributable Gilbert 's disease ) Urine serum betahuman chorionic gonadotropin ( HCG ) serum HCG = negative ( female patient childbearing potential ) Patient legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure Consult physician experience care management subject hepatitis B manage/treat subject antihepatitis B core antibody ( HBc ) positive Prior history HIVpositivity ( routine HIV testing require pretreatment ) Positive serology hepatitis B ( HB ) define positive test HBsAg ; addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , hepatitis B DNA test perform positive patient exclude Serious nonmalignant disease ( e.g. , active uncontrolled bacterial , viral , fungal infection ) medical condition ( include psychiatric ) , opinion Principal Investigator ( PI ) would compromise protocol objective Presence symptomatic CNS lymphoma Pregnant lactating female Prior history radiation chemotherapy MCL History allergic reaction attribute compound similar chemical biologic composition ofatumumab agent use study Patients `` currently active '' second malignancy , nonmelanoma skin cancer situ carcinoma cervix breast ; patient consider `` currently active '' malignancy complete anticancer therapy , consider physician less 30 % risk relapse least 25 year lapse Major surgery , diagnostic surgery , within 2 week Patients nonHodgkin lymphoma ( NHL ) MCL Patients must history cardiac disease , define New York Heart Association class II great clinical evidence congestive heart failure ; patient must MUGA scan 2dimensional ( D ) echocardiogram indicate ejection fraction &gt; = 45 % within 42 day prior registration ; method used baseline must use later monitor Unwilling unable follow protocol requirement Any condition Investigator 's opinion deem patient unsuitable candidate receive study drug Received investigational agent within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>